STDY OF EFFICACY&SAFETY OF RCMBNNT C1 INHBTR 4 TRTMNT OF ACUTEATCKS OF ANGIOEDEM

功效研究

• 批准号: 7377855
• 负责人: CHARLES HARVEY KIRKPATRICK
• 金额: $ 0.43万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377855
• 关键词: STDY; EFFICACY&SAFETY; RCMBNNT; C1; INHBTR

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hereditary angioedema is a genetic disease in which patients are susceptible to attacks of swelling under the skin of the face, hands, feet, buttocks, genitalia and intestines. If the attacks affect the tongue or throat, there is a risk of suffocation. The attacks may be brought on by trauma such an injury or dental work and may accompany a menstrual period. Some attacks have no known cause. Patients with hereditary angioedema are not able to make a protein called C1 inhibitor (C1 INH). In most patients the attacks can be prevented by treatment with low doses of male hormones (androgens). Some patients, especially young women, are not able to use androgens because they can cause acne, growth of facial hair and weight gain. Androgens cannot be used during pregnancy. Androgen treatment stimulates the body to make C1 inhibitor. In the United States, treatment of acute attacks involves use of narcotics for pain and supportive treatments such as replacement of fluids. For some patients, infusions of fresh frozen blood plasma are beneficial. In Europe, the C1 inhibitor is commercially available and is the standard of care for treatment of acute attacks in patients with hereditary angioedema. The purpose of this research study is to study the safety and clinical effects of IV infusions of C1 inhibitor in patients with hereditary angioedema during acute attacks that affect the intestines, genitalia and/or face and throat. The goals are to learn which doses are effective and how fast the drug works. These results will be compared with those observed in patients who get an inactive IV infusion (placebo). The long term goal of the study which will be done in 15-20 centers in the Country is to get information for an application to the U.S. Food and Drug Administration for approval of C1 inhibitor as a treatment for hereditary angioedema in the United States

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。遗传性血管性水肿是一种遗传性疾病，患者容易在面部、手部、足部、臀部、生殖器和肠道的皮肤下发生肿胀。如果攻击影响舌头或喉咙，有窒息的危险。这种攻击可能是由创伤（例如受伤或牙科工作）引起的，并且可能伴随月经期。有些攻击没有已知的原因。患有遗传性血管性水肿的患者不能产生一种称为C1抑制剂（C1 INH）的蛋白质。 在大多数患者中，可以通过低剂量的雄性激素（雄激素）治疗来预防发作。有些患者，特别是年轻女性，不能使用雄激素，因为它们会导致痤疮，面部毛发生长和体重增加。怀孕期间不能使用雄激素。雄激素治疗刺激身体产生C1抑制剂。 在美国，急性发作的治疗包括使用麻醉剂止痛和支持性治疗，如补液。对于某些患者，输注新鲜冷冻血浆是有益的。在欧洲，C1抑制剂是市售的，是治疗遗传性血管性水肿患者急性发作的标准治疗。本研究的目的是研究在影响肠道、生殖器和/或面部和咽喉的遗传性血管性水肿急性发作期间IV输注C1抑制剂的安全性和临床效果。目标是了解哪些剂量是有效的，以及药物起效的速度。将这些结果与接受非活性IV输注（安慰剂）的患者中观察到的结果进行比较。本研究将在美国的15-20个中心进行，其长期目标是获得向美国食品药品监督管理局申请批准C1抑制剂作为美国遗传性血管性水肿治疗的信息